Evommune, Inc. Earnings Per Share (Diluted)
Evommune, Inc. (EVMN) reported Earnings Per Share (Diluted) of -$0.89 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareDiluted · last filed 2026-08-06
- Evommune, Inc. earnings per share, diluted for the quarter ending 2026-06-30 was -$0.89.
- Evommune, Inc. earnings per share, diluted for the quarter ending 2026-03-31 was -$0.64.
- Evommune, Inc. earnings per share, diluted for the quarter ending 2025-12-31 was -$1.42.
- Evommune, Inc. earnings per share, diluted for the quarter ending 2025-09-30 was -$8.07.
- Evommune, Inc. earnings per share, diluted for fiscal 2025 was -$11.22.
- Evommune, Inc. earnings per share, diluted for fiscal 2024 was -$45.29.
| Period end | Earnings Per Share, Diluted 3 month | Earnings Per Share, Diluted 6 month | Earnings Per Share, Diluted 9 month | Earnings Per Share, Diluted 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$0.89 10-Q · filed 2026-08-06 | -$1.54 10-Q · filed 2026-08-06 | -$2.75 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$4.15 derived: net income ÷ weighted average shares · filed 2026-08-06 |
| 2026-03-31 | -$0.64 10-Q · filed 2026-05-07 | -$1.86 derived: net income ÷ weighted average shares · filed 2026-05-07 | -$3.40 derived: net income ÷ weighted average shares · filed 2026-05-07 | -$5.36 derived: net income ÷ weighted average shares · filed 2026-08-06 |
| 2025-12-31 | -$1.42 derived: net income ÷ weighted average shares · filed 2026-03-05 | -$3.80 derived: net income ÷ weighted average shares · filed 2026-03-05 | -$7.08 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$11.22 10-K · filed 2026-03-05 |
| 2025-09-30 | -$8.07 10-Q · filed 2025-12-11 | -$16.88 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$26.36 10-Q · filed 2025-12-11 | -$39.89 derived: net income ÷ weighted average shares · filed 2026-08-06 |
| 2025-06-30 | -$8.80 10-Q · filed 2026-08-06 | -$18.29 10-Q · filed 2026-08-06 | -$31.83 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$42.30 derived: net income ÷ weighted average shares · filed 2026-08-06 |
| 2025-03-31 | -$9.48 10-Q · filed 2026-05-07 | -$23.04 derived: net income ÷ weighted average shares · filed 2026-05-07 | -$33.51 derived: net income ÷ weighted average shares · filed 2026-05-07 | |
| 2024-12-31 | -$13.56 derived: net income ÷ weighted average shares · filed 2026-03-05 | -$24.04 derived: net income ÷ weighted average shares · filed 2026-03-05 | -$45.29 10-K · filed 2026-03-05 | |
| 2024-09-30 | -$10.47 10-Q · filed 2025-12-11 | -$30.69 10-Q · filed 2025-12-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |